Home » Business News » 2011 » June » June 8, 2011

Hope of a Healthy Sector to Drive Pharmaceuticals -- Research Report on Orexigen Therapeutics, Inc. and VIVUS, Inc.

June 8, 2011 - MACAU

Today, announced its research report highlighting Orexigen Therapeutics, Inc. (NASDAQ: OREX) and VIVUS, Inc. (NASDAQ: VVUS). Full content and research is available at

Several new innovations within the healthcare field have buoyed an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock -- responding to the needs of millions of people. Occupational projections show concentrated growth within the industry, a result of the growing demand for improved medical care in both developed and developing economies. The global medical industry is one of the world's fastest growing, absorbing over 10% of the Gross Domestic Product of most developed countries.

Equity Markets has reviewed Orexigen Therapeutics, Inc. as a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of Obesity. Its combination product candidates targeted for obesity are Contrave which has completed Phase III clinical trials, and Empatic, which has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release (SR) formulation. On Friday, Orexigen said it was putting its obesity-drug program on hold until it receives further guidance from U.S. regulators on the approval path for such medications. The full research report on Orexigen Therapeutics, Inc. (NASDAQ: OREX) is available here:

Equity Markets is covering VIVUS, Inc. as it is also a growing biopharmaceutical company focused on the development and commercialization of therapeutic products for underserved markets. Its investigational product pipeline includes two late-stage clinical product candidates. One of these investigational products, Qnexa, has completed Phase III clinical trials for Obesity, and Phase II clinical trials for Diabetes and obstructive sleep apnea. In December 2009, it submitted a new drug agreement (NDA) to the United Stated Food and Drug Administration (FDA) for Qnexa. The full research report on VIVUS, Inc. (NASDAQ: VVUS) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.


Samuel Littman
Email Contact


Comment on this story